Tuesday desk. Zero new EU licences. The 17 Sep CHMP opinion on denecimig is not an EU licence.
#CHMP
@europepharmatoday.bsky.social
@europepharmatoday.bsky.socialTuesday desk. Zero new EU licences. The 17 Sep CHMP opinion on denecimig is not an EU licence.
#CHMP
@europepharmatoday.bsky.socialThursday desk: sefaxersen IgAN goal, enicepatide phase 2, dazodalibep Sjögren, Novo 2030 ambitions, Sepalna CHMP opinion. None is an EU MA.
https://europepharmatoday.com/pulse/2026-09-24?utm_source=bluesky&utm_medium=social&utm_campaign=pulse-2026-09-24
#CHMP
@europepharmatoday.bsky.socialTuesday evening leftovers: Gevalka, Zeydovio, Tecvayli 2L vote, Stivarga sale, Sanofi–Cheplapharm. None is an EU MA.
https://europepharmatoday.com/pulse/2026-09-22?utm_source=bluesky&utm_medium=social&utm_campaign=pulse-2026-09-22
#CHMP
@europepharmatoday.bsky.socialTuesday leftovers: CHMP opinions, an Article 31 keep, an FDA gene therapy, a signed deal. None is an EU MA.
https://europepharmatoday.com/pulse/2026-09-22?utm_source=bluesky&utm_medium=social&utm_campaign=pulse-2026-09-22
#CHMP
@jyves94.bsky.socialLe #CHMP 💊 de l’ #EMA 🇪🇺 a adopté un avis favorable recommandant une extension d’indication pour le #Teclistamab ( #Tecvayli) dans le traitement des patients adultes atteints d’un #MyélomeMultiple 🩸 en R/R ayant déjà reçu au moins un traitement.
www.onclive.com/view/chmp-re...
@europepharmatoday.bsky.socialSunday leftovers: CHMP opinions, a G-BA deletion, a NICE TA, an FDA combo. None is an EU MA.
https://europepharmatoday.com/pulse/2026-09-20?utm_source=bluesky&utm_medium=social&utm_campaign=pulse-2026-09-20
#CHMP
@kpulse360.bsky.social12 nouveaux médicaments recommandés – relevé du CHMP
Le CHMP a recommandé 12 nouveaux médicaments lors de sa réunion de septembre 2026.
https://infos.kanibal-studio.com/12-nouveaux-medicaments-recommandes-releve-du-chmp-5ce3cd
@europepharmatoday.bsky.socialCHMP recommended 12 medicines and 11 extensions. Opinions, not EU MAs.
https://europepharmatoday.com/news/chmp-september-2026-meeting-highlights?utm_source=bluesky&utm_medium=social&utm_campaign=chmp-september-2026-meeting-highlights
#CHMP
@europepharmatoday.bsky.socialTwo CHMP opinions today. Neither is an EU MA.
Frehemgo in haemophilia A. Pepaxti toward 3L myeloma.
https://europepharmatoday.com/pulse/2026-09-17?utm_source=bluesky&utm_medium=social&utm_campaign=pulse-2026-09-17
#CHMP
@europepharmatoday.bsky.socialCHMP agenda ≠ outcomes. EMA’s 14–17 Sep list is a work list — opinions land Friday.
https://europepharmatoday.com/news/chmp-september-2026-meeting-agenda-week-watch?utm_source=bluesky&utm_medium=social&utm_campaign=chmp-september-2026-meeting-agenda-week-watch
#CHMP
@ema.europa.euThe agenda of EMA's human medicines committee #CHMP is now published. Find out what medicines will be discussed this month 💊💉 www.ema.europa.eu/en/events/co... The committee highlights will be released on Friday.
@europepharmatoday.bsky.socialHARBOR miss ≠ CHMP opinion. Del-desiran missed vHOT in ~150 people with DM1. Not an EU MA.
https://europepharmatoday.com/news/novartis-del-desiran-harbor-dm1-miss-september-2026?utm_source=bluesky&utm_medium=social&utm_campaign=novartis-del-desiran-harbor-dm1-miss-september-2026
#CHMP
